United States Health

Tvardi Therapeutics (NASDAQ:TVRD) reported a Q2 2026 net loss of $6.5 million as R&D spending declined to $4 million.

Neumora Therapeutics (NASDAQ:NMRA) reported a Q2 2026 net loss of $43.1 million, narrowing from $52.7 million a year earlier.

Outlook Therapeutics (NASDAQ:OTLK) reported a fiscal Q3 net loss of $20.3 million as it prepares to launch FDA-approved wet AMD treatment LYTENAVA.

TuHURA Biosciences (NASDAQ:HURA) ended Q2 2026 with $1 million in cash as R&D spending rose to $6.6 million amid increased clinical activity.

Lantern Pharma (NASDAQ:LTRN) reported a Q2 operating loss of $3.5 million, down 25%, while emerging LP-300 data showed 8.9-month median progression-free survival in selected patients.

Rein Therapeutics (NASDAQ:RNTX) said its Phase 2 RENEW trial of inhaled LTI-03 has surpassed 25% of planned enrollment of approximately 120 patients.

RCM Technologies (NASDAQ:RCMT) reported second-quarter revenue of $93.8 million, up 20%, while GAAP net income rose to $4.9 million.

Pfizer (NYSE:PFE) and Valneva (NASDAQ:VALN) said the EMA validated their PF-07307405 Lyme vaccine application after Phase 3 efficacy exceeded 70%.

Rockwell Medical (NASDAQ:RMTI) reported second-quarter 2026 net sales of $17.8 million, up 11% year over year, as the healthcare company increased sales to new and existing dialysis customers.

Cullinan Therapeutics (NASDAQ:CGEM), Taiho Oncology, and Taiho Pharmaceutical announced that the global Phase 3 REZILIENT3 trial of zipalertinib plus platinum-based chemotherapy met its primary endpoint of progression-free survival in previously untreated patients with EGFR exon 20 insertion non-small cell lung cancer.

Belite Bio (NASDAQ:BLTE) reported second-quarter 2026 results and announced that the U.S. Food and Drug Administration accepted its New Drug Application for tinlarebant with Priority Review for Stargardt disease type 1.

Pharming (NASDAQ:PHAR) announced the commercial launch of Joenja (leniolisib) in Japan for patients aged 4 years and older with activated PI3K delta syndrome (APDS), following its inclusion on Japan’s National Health Insurance drug price list.